+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

ProMIS Neurosciences Inc (PMN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 51 Pages
  • May 2026
  • GlobalData
  • ID: 1367821
ProMIS Neurosciences Inc (PMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies for neurodegenerative diseases caused by abnormal, misfolded proteins. The company targets conditions such as multiple system atrophy, amyotrophic lateral sclerosis, and Alzheimer’s disease, where toxic protein conformations drive disease progression. Its lead program, PMN310, is a monoclonal antibody being developed for Alzheimer’s disease. ProMIS uses a patented technology platform to design antibody candidates that selectively recognize and neutralize toxic forms of proteins while avoiding interference with the normal, healthy proteins required for cellular function. ProMIS is headquartered in Toronto, Ontario, Canada.

ProMIS Neurosciences Inc Key Recent Developments

  • Apr 13, 2026: ProMIS Neurosciences to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
  • Mar 19, 2026: ProMIS Unveils Vaccines Targeting ALS and Parkinson's Disease
  • Jan 30, 2026: ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
  • Dec 10, 2025: ProMIS Neurosciences Publishes Peer-Reviewed Study on Selective Targeting of Toxic Oligomers and Reduced ARIA Risk

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • ProMIS Neurosciences Inc - Key Facts
  • ProMIS Neurosciences Inc - Key Employees
  • ProMIS Neurosciences Inc - Key Employee Biographies
  • ProMIS Neurosciences Inc - Major Products and Services
  • ProMIS Neurosciences Inc - History
  • ProMIS Neurosciences Inc - Company Statement
  • ProMIS Neurosciences Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • ProMIS Neurosciences Inc - Business Description
  • R&D Overview
  • ProMIS Neurosciences Inc - Corporate Strategy
  • ProMIS Neurosciences Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • ProMIS Neurosciences Inc - Strengths
  • ProMIS Neurosciences Inc - Weaknesses
  • ProMIS Neurosciences Inc - Opportunities
  • ProMIS Neurosciences Inc - Threats
  • ProMIS Neurosciences Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • ProMIS Neurosciences Inc, Medical Equipment, Deals By Year, 2020 to YTD 2026
  • ProMIS Neurosciences Inc, Medical Equipment, Deals By Type, 2020 to YTD 2026
  • ProMIS Neurosciences Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 13, 2026: ProMIS Neurosciences to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
  • Mar 19, 2026: ProMIS Unveils Vaccines Targeting ALS and Parkinson's Disease
  • Jan 30, 2026: ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
  • Dec 10, 2025: ProMIS Neurosciences Publishes Peer-Reviewed Study on Selective Targeting of Toxic Oligomers and Reduced ARIA Risk
  • Dec 01, 2025: ProMIS Neurosciences to Participate in 8th Annual Evercore Healthcare Conference
  • Dec 01, 2025: ProMIS Neurosciences Publishes Study Supporting Plasma pTau as Early Predictor in Alzheimer’s Trials
  • Nov 12, 2025: ProMIS Neurosciences Reports Third Quarter 2025 Financial Results and Corporate Highlights
  • Oct 22, 2025: ProMIS Neurosciences Appoints Slanix Paul Alex to Board
  • Mar 31, 2025: ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • ProMIS Neurosciences Inc, Key Facts
  • ProMIS Neurosciences Inc, Key Employees
  • ProMIS Neurosciences Inc, Key Employee Biographies
  • ProMIS Neurosciences Inc, Major Products and Services
  • ProMIS Neurosciences Inc, History
  • ProMIS Neurosciences Inc, Other Locations
  • ProMIS Neurosciences Inc, Subsidiaries
  • ProMIS Neurosciences Inc, Key Competitors
  • ProMIS Neurosciences Inc, Ratios based on current share price
  • ProMIS Neurosciences Inc, Annual Ratios
  • ProMIS Neurosciences Inc, Interim Ratios
  • ProMIS Neurosciences Inc, Medical Equipment, Deals By Year, 2020 to YTD 2026
  • ProMIS Neurosciences Inc, Medical Equipment, Deals By Type, 2020 to YTD 2026
  • ProMIS Neurosciences Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • ProMIS Neurosciences Inc, Ratio Charts
  • ProMIS Neurosciences Inc, Medical Equipment, Deals By Year, 2020 to YTD 2026
  • ProMIS Neurosciences Inc, Medical Equipment, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Grifols SA
  • Filana Therapeutics Inc
  • Annovis Bio Inc
  • Acumen Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Neurimmune Holding AG
  • Inova Diagnostics Inc
  • Idexx Laboratories Inc
  • Diagnostica Stago Inc
  • Chugai Pharmaceutical Co Ltd
  • Novartis AG
  • Eli Lilly and Co
  • DiaSorin SpA
  • Biogen Inc
  • Anavex Life Sciences Corp
  • Alzheon Inc
  • LeonaBio Inc
  • Eisai Co Ltd
  • AbbVie Inc
  • Kalgene Inc
  • Biohaven Pharmaceuticals Inc
  • Prothena Biosciences Inc
  • WaveBreak Therapeutics Ltd
  • Cognition Therapeutics Inc
  • Alzinova AB
  • AC Immune SA